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Causes of mortality in TSC 
 
 
ABSTRACT  
 
Aim   
The causes of death in patients with tuberous sclerosis complex (TSC) have rarely 
been studied, with only one published account, which was reported from the Mayo 
Clinic in 1991. We aimed to investigate mortality in a large cohort of TSC patients from 
one of two national referral clinics in the UK.  
 
Method 
We identified 284 patients who attended Bath TSC clinic between 1981 and 2015 and 
ascertained causes of death by reviewing medical records, death certificates and post-
mortem reports.  
 
Results 
Sixteen patients died from complications of TSC: eight from TSC kidney diseases; four 
from Sudden Unexpected Death in Epilepsy (SUDEP); two from 
lymphangioleiomyomatosis; one from a subependymal giant cell astrocytoma; and 
one from a pancreatic malignancy. The median age of death was 33 years (IQR 26-
46). Mortality was significantly more common in patients with learning-disability than 
in those without (13/135 (9%) vs 3/131 (2%), P = 0.02) (two-tailed Fisher exact test).   
 
Interpretation 
Renal disease is a major cause of mortality in TSC. Lifelong surveillance and early 
intervention is warranted. SUDEP is also an important cause of mortality. Patients with 
learning disabilities are at significantly greater risk of early mortality and this implies 
the need for greater vigilance for TSC related complications in this group. Female 
patients are vulnerable to pulmonary and renal disease. Pancreatic lesions are a rare 
but potentially treatable cause of mortality. 
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What this paper adds 
 
1. SUDEP is an important cause of mortality in TSC patients. 
2. Patients with learning disabilities are at significantly greater risk of 
early mortality.  
3. Female patients are more vulnerable to renal and pulmonary 
disease compared with male patients.  
4. Less well-known manifestations of TSC, such as pancreatic 
malignancy, are important causes of death.  
 
 
Tuberous Sclerosis Complex (TSC) is a genetic condition caused by 
mutations in the tumour suppressor genes TSC1 and TSC2, located on 
chromosomes 9 and 16 respectively.[1, 2] Approximately two-thirds of 
cases occur sporadically and the overall incidence has been estimated to 
be 1 per 5,800 live births.[3] 
 
The protein products of TSC1 and TSC2, hamartin and tuberin 
respectively, function together within the cell and have an inhibitory effect 
on the mammalian target of rapamycin (mTOR), a protein kinase that 
influences cell growth and division through the regulation of protein 
formation.[4] Pathogenic mutations in TSC1 or TSC2 lead to over-
activation of the mTOR pathway, which can cause growth of benign 
tumours (hamartomas) in various organs, such as the brain, kidneys, skin, 
heart, lungs and bones, these hamartomas being the clinical hallmarks of 
the disease.[5] 
 
TSC is a multisystem disorder that can affect almost any organ in the 
body. The skin is commonly affected with lesions such as facial 
angiofibromatosis, hypomelanic macules, shagreen patches, forehead 
fibrous plaques and periungual fibromas.[3] However, the most serious 
morbidity is caused by lesions in the central-nervous, renal, pulmonary 
and endocrine systems.[6] Epilepsy is a common presenting symptom 
and medical problem in TSC and it is thought to arise secondary to cortical 
and subcortical tubers.[7] The majority of patients with TSC present with 
seizures during infancy, often with epileptic spasms, and many go on to 
suffer with intractable epilepsy throughout life.[7] Sub-ependymal giant 
cell astrocytomas (SEGAs) are slow growing benign tumours, seen in 5% 
to 20% of individuals with TSC.[8] As they grow adjacent to the foramen 
of Monro, they can cause clinical problems by blockage of cerebrospinal 
fluid pathways within the ventricular system leading to obstructive 
hydrocephalus.[8] More than 80% of TSC patients have kidney 
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angiomyolipomas. These lesions can haemorrhage which may be life-
threatening or cumulative bleeds may lead to destruction of viable renal 
tissue and ultimately lead to renal failure.[9] Pulmonary 
lymphangioleiomyomatosis (LAM) occurs almost exclusively in female 
patients and they can present with progressive shortness of breath, 
recurrent pneumothoraces and deterioration in lung function.[10]  
 
The causes of death in this group of patients have rarely been studied 
with the one published account from the Mayo Clinic appearing in 1991.[6] 
This study reported that the majority of patients died due to renal disease 
or SEGA lesions. We are conducting this study to investigate the causes 
of death in a more contemporary population of patients to investigate 
whether causes of mortality have changed over time or differ within a 
different healthcare system. The results of such a study may help 
clinicians and policy makers to decide where best to focus efforts and 
resources to reduce mortality in the future. 
  
Methods 
 
The Bath TSC clinic is a specialist supra-regional clinic and sees patients 
with TSC of all ages. We reviewed a database of all patients who had 
attended the Bath TSC clinic from 1981 to 2015 inclusive.  
 
Of these patients, we identified 284 patients with a definite diagnosis of 
TSC, as defined by the International Tuberous Sclerosis Complex 
Consensus Group.[11] We reviewed the medical records, including 
medical notes, radiology images, and where applicable, death certificates 
and post-mortem reports, in order to determine the age and cause of 
death. Patients were confirmed to be either alive or deceased through 
clinic records or through GP records if not actively attending clinic. If the 
death certificate or post-mortem details were not present in the medical 
records, they were obtained via the hospital bereavement services, 
primary care facilities, or requested from the General Register Office. 
Additionally, details regarding patient demographics and clinical details 
were reviewed. Ethical approval was not required but all patient details 
were anonymised.  
 
This is a clinic cohort in which there was heterogeneity in terms of 
administered investigations. For example, not all patients were 
administered psychometric tests in a consistent fashion, but some tests 
were requested and administered when an initial clinical screen of abilities 
identified areas of concern. We divided the clinic cohort into two groups: 
those with (“LD”) or without (“non-LD”) learning disabilities. Patients were 
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given these diagnoses of learning disability based on their abilities to 
understand new or complex information or to learn new skills, or their 
ability to cope or live independently, and with such inabilities having 
started before adulthood. Although these categorisations were made on 
the basis of clinical assessment rather than according to any 
measurement tool, they broadly concord with the definitions of learning 
disability defined by the UK Department of Health.[12] 
 
Results  
  
284 patients with a definite diagnosis of Tuberous Sclerosis Complex, 
attended the Bath TS clinic from 1981 to 2015 and all were included in 
this study. There were 149 (52%) patients with learning disabilities. The 
median age of LD patients was 25 years interquartile range (IQR) 15-36, 
and the median age of patients without LD was 28 years (IQR 17-43). 
There was no gender difference in this cohort. 
 
The median follow up duration for all clinic patients was 8 years (IQR 3-
17). Forty-one patients had a follow up duration of >20 years, 92 patients 
had a follow up duration of 10-20 years and 151 had a follow up duration 
of less than 10 years.  
 
Eighteen patients (11 female and 7 male) in the clinic cohort died during 
this period. In two patients, the cause of death was considered not to be 
directly attributable to TSC. One patient died from ischaemic heart 
disease at age 80 years, and the other patient from pulmonary embolism, 
secondary to deep venous thrombosis of the leg at age 33 years. The 
pulmonary embolism was confirmed by CT scan and there was no 
evidence of LAM.  
 
The age range of the 16 patients who died directly due to TSC was 17 to 
60 years. Median age of death in this group was 33 years (IQR 26-46). 
(Figure 2) Seventy-one out of 284 patients in the clinic cohort where 
children aged 0-16 years.  
 
In the mortality group, 13 out of 16 patients who died of causes directly 
related to TSC, had learning disability. Mortality was significantly more 
common in the LD group than the non-LD patients (9% vs 2%, Fisher 
exact test, p = 0.02, Table 1).  
 
Death due to renal causes was seen in eight patients (6 female and 2 
male). Three of these patients had chronic kidney failure and one of those 
three patients had polycystic kidney disease. Three died secondary to 
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acute haemorrhage from renal angiomyolipomas. One of those three 
patients had had kidney haemorrhage requiring multiple embolisations, 
one had bilateral multiple angiomyolipomas and diffusely abnormal 
kidneys. The remaining two patients died due to renal cell carcinoma.  
 
In our clinic cohort, four deaths were attributed to sudden unexplained 
death in epilepsy (SUDEP), one of which occurred in a case with no 
identified learning disabilities. SUDEP was defined according to the 
criteria published by Devinsky et al.[13] Age at death was between 18 and 
40 years. All four patients had developed epilepsy before the age of 16 
years, and suffered from more than three generalised tonic-clonic 
seizures per year. Three patients were on antiepileptic monotherarpy with 
carbamazepine, and one patient was on a combination of carbamazepine 
with clonazepam and also had a working VNS (vagus nerve stimulator) in 
situ at the time of death. None of these patients were identified as being 
in status epilepticus at the time of death but they were all assessed to 
have had an epileptic seizure immediately prior to death. In these cases, 
age at the time of death was between 18 and 40 years.  
 
Pulmonary lymphangioleiomyomatosis (LAM) was the stated cause of 
death in two patients, both of whom were female. One patient, aged 17 
years, had developed heart failure due to LAM lesions in the lung, and the 
second patient, aged 19 years, died in her sleep secondary to massive 
pulmonary haemorrhage.  
 
One patient died at age 33 years due to a metastatic non-secreting 
neuroendocrine pancreatic tumour.  
 
One patient died aged 26 years due to SEGA. He was referred to our 
service in 1989 and after neurosurgeons had already recommended a 
palliative approach because they assessed his SEGA to be inoperable at 
the time of diagnosis. 
 
Discussion  
 
This study, compared with the previously published report, provides 
important new insights into the causes of death in this patient group.[6] It 
confirmed renal causes as being the commonest cause of early death but 
it has also demonstrated that SUDEP is a significant and previously 
unreported risk in TSC. Patients with LD are significantly more likely to 
suffer premature death, and female patients are more at risk of death 
secondary to angiomyolipoma and LAM compared with males. In contrast 
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with the previous report, SEGA was an uncommon cause of death. There 
were no deaths during childhood. 
 
This was a retrospective study design and was based on a clinic 
population, which creates the main limitation of this study and limits the 
degree of generalisability of its findings. Specialist clinics tend to ascertain 
more severe cases and we would anticipate this patient sample to have 
more medical issues and co-morbid factors than the overall population of 
people with TSC. The gender balance and prevalence of LD in our cohort, 
however, was similar to previously reported population based TSC 
cohorts, suggesting that this clinic population was not grossly dissimilar 
from the TSC population at large.[9, 14] A relative strength of this study, 
compared with the Mayo Clinic report, is that it relied not only on death 
certificates, but also on other sources, such as post-mortem examination 
and medical notes. Studies have shown that death certificates can be 
completed inaccurately and can be misleading when relied upon as the 
sole source of mortality data.[15] 
 
In our series, the median age of death was 33 years (IQR 26-46). None 
of the cases died in the paediatric age range (<16 years). Although we 
would expect TSC complications become more prevalent with increasing 
age and possibly not to cause death in the paediatric age group, this 
finding contrasts with the earlier study, where 40% of the deaths were in 
children.[8] We believe that our study’s finding of absent mortality in 
children and only single case of mortality secondary to SEGA reflects a 
period effect relating to increased awareness of this condition, improved 
surveillance within a specialist clinic population, and successful treatment 
within a specialist neurosurgical centre that has acquired significant 
experience in dealing with these mid-line tumours[8]. Although not 
reported from our clinic population, mortality in childhood in TSC may 
occur secondary to cardiac rhabdomyomas, which are TSC-related 
hamartomas that grow in foetal life and can cause a significant problem 
around the time of birth by such mechanisms as obstruction to blood flow 
or life-threatening arrhythmias. The cardiac rhabdomyomas tend to 
regress in size after the perinatal period and are unlikely to be a cause of 
death in cases ascertained through a TSC clinic, and this is a factor that 
would tend to bias downwards estimates of death in childhood in studies 
such as ours.[16]  
 
In the surviving cohort, there was no significant gender imbalance (132 
female and 134 male patients). The mortality in females was higher that 
of males (10 vs 6) but this difference was not statistically significant (two-
tailed Fisher exact test for proportions of females vs males dying, P = 
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0.44). Female patients died predominantly secondary to renal and lung 
complications.  Figure 3 shows cause of death by gender.  
 
It is well known that pulmonary LAM occurs almost exclusively in 
women[10] and, therefore, it is not surprising that the two fatalities in this 
study secondary to LAM were females. One possible explanation for 
symptomatic LAM occurring almost exclusively in females is that LAM 
lesions are thought to express oestrogen and progesterone receptor 
proteins.[17] It is also noticeable that the two deaths associated with LAM 
occurred in women of child-bearing age, where there is exposure to higher 
levels of circulating oestrogen than at pre-pubertal or post-menopausal 
ages.[18] There are some suggestions that oestrogen-containing 
contraceptives can exacerbate pulmonary LAM lesions.[19,20] 
 
In this study, six out of the eight patients who died from renal causes were 
female. One previous population-based study has shown 
angiomyolipomas to be slightly, but not significantly, more prevalent in 
women but the difference in prevalence is not so large as to explain the 
differential renal associated mortality between the genders.[9,21] It is 
possible that the differential mortality is explained by the fact that 
angiomyolipomas also express oestrogen receptors, thus making them 
more likely to grow to a dangerous size in the female population, but it 
might also be a chance finding given that it is a relatively uncommon cause 
of death in a moderately-sized study population.  
   
Thirteen of the patients who died had learning disabilities. The increased 
risk of early mortality in LD patients has not previously been reported.  LD 
is a recognised feature of TSC and seen in approximately 50% of patients, 
[22] and in our cohort, 52% had LD. The increased risk of early mortality 
in the LD population of TSC patients is plausible for several reasons. 
Firstly, the LD population may be prone to having more hamartomas than 
non-LD patients. One study has previously reported that patients with LD 
have more TSC related renal hamartomas.[23] Secondly, patients with 
learning disabilities are at much higher risk of epilepsy than patients 
without learning disabilities, and therefore also at higher risk of SUDEP.[7] 
Finally, patients with LD are less likely to be able to communicate 
symptoms to their carers and their complications may not come to medical 
attention until they are more advanced.  Based on these findings, patients 
with learning disabilities merit regular and close surveillance in order to 
minimise the risk of premature death.   
 
Death due to renal causes was the commonest cause of death in this 
group. Three patients died due to renal bleeding from angiomyolipomas 
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without any preceding history of renal failure. Three died due to renal 
failure secondary to extensive angiomyolipoma formation and recurrent 
bleeds. Two patients died secondary to renal cell carcinoma. These 
findings support the need for regular surveillance of this population for the 
development of potentially fatal renal lesions. 
 
In our study four deaths were attributed to SUDEP. No SUDEP cases 
have previously been reported in TSC. Deaths due to status epilepticus 
have been reported in TSC.[24] 
 
All patients had multiple risk factors for SUDEP.  They were adults aged 
between 18 and 40 years at the time of death. SUDEP has been reported 
to be four times more likely in adults compared with children, and the peak 
age categories at time of death from this cause are between 20 to 40 
years.[25] All four patients had developed epilepsy before the age of 16, 
suffered from multiple  generalised tonic-clonic seizures per year and 
were on treatment with carbamazepine. Three of these patients had 
learning disabilities. Previous reports have linked all these factors to 
SUDEP.[26] It is also possible in TSC patients that residual cardiac 
rhabdomyomas may predispose patients to cardiac arrhythmia in the 
context of an epileptic seizure. Interestingly, two post-mortem reports of 
the SUDEP cases reported the presence of cardiac rhabdomyomas on 
post-mortem examination. These patients were being monitored in the 
hospital at the time of death and their ECG monitoring showed changes 
just seconds before their death. The ECG changes and the presence of 
rhabdomyomas suggest that the cause of death could be cardiac rather 
than cerebral.  
  
One patient died due to a metastatic pancreatic tumour. Pancreatic 
tumours have been reported in individuals with Tuberous Sclerosis 
Complex and the mTOR pathway appears to be activated in pancreatic 
cancer cells.[27, 28] 
 
We have recently seen two TSC patients with pancreatic tumours who are 
under investigation and treatment. It is incorrect to assume that all 
pancreatic lesions in individuals with TSC are benign and necessitate no 
treatment. All TSC patients should probably have intermittent abdominal 
MRI scans to check for pancreatic tumours as these tumours are not 
always easily picked up during kidney US scan surveillance. The 
International Tuberous Sclerosis Complex Consensus Group 
recommends abdominal MRI scan to detect pancreatic tumours.[11]    
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Eight patients received mTOR inhibitors such as rapamycin and 
everolimus. Two patients received this treatment due to SEGA, one due 
to epilepsy, 4 due to angiomyolipomas and one due to pancreatic tumour. 
None of the patients who died in this cohort had ever received any mTOR 
inhibitors. mTOR inhibition has only recently become available for TSC 
patients in the UK and it is impossible to know if use of mTOR inhibitors 
would have had any impact on the mortality rate reported in this 
observational study.  
 
In conclusion, this study has emphasised that renal disease is a major 
cause of mortality in TSC patients. We believe that lifelong surveillance of 
renal lesions, to enable appropriate management of potentially life-
threatening complications, is warranted. The study has revealed also that 
SUDEP is a significant cause of mortality in these patients. Patients and 
carers should be warned about this risk. In our cohort, LD patients were 
at significantly greater risk of early mortality and this indicates the need 
for greater vigilance in these patients for the development of lesions, and 
indeed of symptoms that they may not be able to communicate clearly to 
their carers. Female patients are particularly vulnerable to pulmonary and 
renal disease. The mortality from pulmonary disease in young women 
provides a strong argument that all post-pubertal female TSC patients 
should be screened for LAM and treated appropriately. Finally, pancreatic 
lesions, although rarely reported in TSC, are a reported cause of mortality 
and they should be looked for in TSC patients, not just by means of 
abdominal ultrasound, which is a relatively insensitive investigation, but 
also with intermittent abdominal magnetic resonance imaging, as is stated 
within the International Tuberous Sclerosis Complex 
recommendations.[11]   
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Figure 1: Shows the age, gender, and year of death of those patients who 
died from causes related to TSC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Age category in 2015 of surviving patients or age at death in 
patients within the mortality cohort. 
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Figure 3: Causes of death and patient gender  
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Table 1: Comparison of mortality in patients with learning disabilities and 
patients without learning disabilities; two-tailed Fisher exact test, P=0.02.      
 
